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Abstract
Background: African Americans (AAs) have lower lung function, higher blood pressure variability (BPV) and
increased risk for hypertension and cardiovascular disease (CVD) compared with whites. The mechanism through
which reduced lung-function is associated with increased CVD risk is unclear.
Methods: We evaluated the association between percent predicted lung-function and 24-hour BPV in 1008 AAs
enrolled in the Jackson Heart Study who underwent ambulatory blood pressure (BP) monitoring. Lung-function was
assessed as forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and the ratio of FEV1-to-FVC
during a pulmonary function test using a dry rolling sealed spirometer and grouped into gender-specific quartiles.
The pairwise associations of these three lung-function measures with two measures of 24-hour BPV, (1) day-night
standard deviation (SDdn) and (2) average real variability (ARV) were examined for systolic BP (SBP) and, separately,
diastolic BP (DBP).
Results: SDdn of SBP was not associated with FEV1 (mean ± standard deviation from lowest-to-highest quartile:
9.5 ± 2.5, 9.4 ± 2.4, 9.1 ± 2.3, 9.3 ± 2.6; p-trend = 0.111). After age and sex adjustment, the difference in SDdn of SBP
was 0.0 (95 % CI −0.4,0.4), −0.4 (95 % CI −0.8,0.1) and −0.3 (95 % CI −0.7,0.1) in the three progressively higher
versus lowest quartiles of FEV1 (p-trend = 0.041). Differences in SDdn of SBP across FEV1 quartiles were not
statistically significant after further multivariable adjustment. After multivariable adjustment, no association was
present between FEV1 and ARV of SBP or SDdn and ARV of DBP or when evaluating the association of FVC and
FEV1-to-FVC with 24-hour BPV.
Conclusion: Lung-function was not associated with increased 24-hour BPV.
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Background
Over 40 million US adults have reduced lung function,
defined by low forced vital capacity (FVC) or forced ex-
piratory volume in 1 s (FEV1) [1]. Lower lung function
has been associated with higher risk for all-cause mor-
tality in African Americans (AAs) compared with
whites [2–4]. Low FVC and FEV1 have also been
associated with an increased risk for cardiovascular dis-
ease (CVD) incidence in several studies that include
African Americans [1, 5–8]. However, there are few re-
ports on lung function and CVD mortality in AAs ver-
sus whites, but AAs have a higher burden of CVD risk
factors than whites [2–4]. The mechanisms by which
reduced lung function increases the risk for CVD are
unclear.
Within individuals, blood pressure (BP) fluctuates
from beat-to-beat, throughout the course of the day and
over longer periods of time [9–11]. Similar to reduced
lung function, high BP variability (BPV) has been
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associated with increased CVD risk [11, 12]. Reduced
lung function is associated with several correlates of
high BPV including older age, higher mean systolic BP
(SBP) and inflammation [13–15]. Studies have suggested
that an association exists between reduced lung function
and increased BPV [10, 11]. However, prior studies have
assessed BPV using beat-to-beat measurements during a
5-minute recording and short-term BPV may be directly
influenced by breathing mechanics. In contrast, BP mea-
sured repeatedly over a longer time period, such as with
ambulatory blood pressure monitoring (ABPM), may be
more useful in evaluating the association between lung
function and BPV.
AAs have lower lung function and higher BPV com-
pared to whites, but few studies have conducted ABPM
in AAs [16, 17]. The Jackson Heart Study (JHS), an ex-
clusively AA cohort, assessed BPV over a 24-h period
using ABPM in > 1000 participants. The aim of the
current study was to evaluate the association between
lung function, assessed by percent predicted FEV1 and
FVC, with BPV assessed by 24-hour ABPM in adult AAs
[18]. The association between the percent predicted
FEV1-to-FVC ratio, a measure of airway obstruction,
and BPV was also evaluated.
Methods
Study population
The design and conduct of the JHS has been described
previously [19–21]. Briefly, JHS is a prospective,
community-based observational study designed to
evaluate CVD risk among AAs. JHS enrolled 5301 non-
institutionalized AA participants, aged ≥ 21 years, be-
tween 2000 and 2004 from the Atherosclerosis Risk in
the Community (ARIC) site in Jackson, Mississippi
(30 %) and a regionally representative sample of urban
and rural residents from the Jackson, Mississippi
metropolitan tri-county region (Hinds, Madison and
Rankin counties) that were randomly contacted (17 %),
volunteers (22 %), or secondary family members (31 %)
[22]. The current analysis was restricted to JHS partici-
pants who completed 24-hour ABPM at Exam 1 (n =
1148). After excluding participants who did not meet
the International Database on Ambulatory blood pres-
sure monitoring in relation to Cardiovascular Out-
comes (IDACO) criteria [23] for complete ABPM
(described below) and those who did not have valid
lung function measures, the analytic sample included
1008 participants. The JHS protocol was approved by
the Institutional Review Board governing human sub-
jects research. Informed consent was provided by all
participants. The current analysis was approved by the
University of Alabama at Birmingham Institutional
Review Board.
Data collection
The current analysis included data collected during an
in-home study visit, a clinic examination and 24-hour
ABPM period. During the in-home visit, trained study
staff completed questionnaires with each participant.
These questionnaires were used to collect information
on age, sex, physical activity, smoking status and prior
diagnosed co-morbid conditions. During the clinic exam-
ination, trained technicians measured height, weight and
BP, collected blood samples and conducted a pulmonary
function test. In addition, based on self-report and a pill
bottle review, prescription and over the counter medica-
tions taken in the 2 weeks prior to the study visit were re-
corded. Following the clinic examination, participants
were given the opportunity to complete ABPM.
Current smoking was defined by “yes” responses to the
two questions “Have you smoked more than 400 ciga-
rettes in your lifetime?” and “Do you now smoke ciga-
rettes?” Participants who reported smoking more than
400 cigarettes but quit smoking ≥ 1 year were catego-
rized as former smokers. Participants who reported not
having smoked more than 400 cigarettes in their life
were considered never smokers. Pack-years of cigarette
smoking were estimated by multiplying the self-reported
number of packs of cigarettes smoked daily by the self-
reported number of years the person smoked. Using a
modified Baecke questionnaire, duration, frequency and
intensity of physical activity in four domains (active liv-
ing, work, home life and sport) were evaluated on a scale
of 1 to 5 and summed to calculate a total physical activ-
ity score [24]. Higher scores represent more physical ac-
tivity. History of myocardial infarction (MI), coronary
revascularization procedures and stroke were assessed
by self-report. Using height and weight measured during
the clinic examination, body mass index (BMI) was cal-
culated as weight in kilograms divided by height in me-
ters squared and categorized as non-obese (BMI < 30 kg/
m2) or obese (BMI ≥ 30 kg/m2). Clinic BP was measured
twice, separated by 1 min, with an appropriate cuff size
using a Hawksley random zero sphygmomanometer
(Hawksley and Sons Ltd) after participants had rested
for ≥ 5 min. The average of these measurements was re-
corded. Clinic BP control was defined as a mean clinic
SBP < 140 mm Hg and DBP < 90 mm Hg. Total and
high-density lipoprotein (HDL) cholesterol was quanti-
fied by an oxidase method. High-sensitivity C-reactive
protein (CRP) was calculated using the latex particle
immunoturbidimetric assay method. Urinary albumin
and creatinine were quantified from a 24-hour urine col-
lection using the nephalometric immunoassay and en-
zymatic methods, respectively. Spot urine albumin and
creatinine were used for participants for whom 24-hour
urinary albumin or creatinine was not collected. Albu-
minuria was defined as urinary albumin to urinary
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creatinine ratio ≥ 30 mg/g. Estimated glomerular filtra-
tion rate (eGFR) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [25]. Reduced eGFR was defined as a level <
60 ml/min/1.73 m2. Diabetes was defined as a fasting
(≥8 h) serum glucose ≥ 126 mg/dL or hemoglobin A1c ≥
6.5 % or use of insulin or oral hypoglycemic medications
within 2 weeks prior to the clinic examination visit.
Lung function measurements
Three measures of lung function were evaluated: forced
expiratory volume in 1 s (FEV1), forced vital capacity
(FVC) and the ratio of FEV1-to-FVC. FEV1 is the vol-
ume of exhaled gas in 1 s from the beginning of a forced
exhalation. FVC is the total volume of exhaled gas from
the lung. The ratio of these measures, FEV1 divided by
FVC, is used as a marker of airway obstructions. These
were measured in accordance with the 1994 American
Thoracic Society recommendations by a trained techni-
cian during a pulmonary function test using a dry rolling
sealed spirometer. The test was performed until auto-
mated quality checking software (Occupational Market-
ing, Inc., Houston, TX) indicated the American Thoracic
Society acceptability and reproducibility standards were
met or for a maximum of eight attempts. In addition,
each spirometry tracing was visually reviewed and scored
for quality on three distinct aspects: 1) first volume, 2)
second volume and 3) initial effort. Each measure of
lung function was normalized for participant’s age, sex
and height resulting in percent predicted FEV1, FVC
and FEV1-to-FVC, respectively [18].
Ambulatory blood pressure monitoring
An ABPM device (Spacelabs 90207) was fitted on each
participant’s non-dominant arm using an appropriate
cuff size as determined by measuring the arm circumfer-
ence at the midpoint of the extended upper arm. The
ABPM device was programed to record BP every 20 min
for 24-hours. Upon returning the device, the data were
downloaded, automatically evaluated for quality control
and processed using Medifacts International’s Medicom
software (Rockville, MD) customized for the JHS. A valid
ABPM measurement, defined using IDACO criteria, re-
quired participants to have ten or more valid daytime
(10:00 to 20:00) and five or more valid nighttime (00:00
to 06:00) SBP and DBP measurements [23]. Two mea-
sures of BPV were calculated for the current study, day-
night standard deviation (SDdn) and average real vari-
ability (ARV). SDdn of SBP was calculated as the
weighted standard deviation of SBP measured during the
daytime and nighttime [26]. ARV of SBP was calculated
as the average absolute difference between consecutive
SBP readings from the ABPM [12]. SDdn of DBP and
ARV of DBP were also calculated.
Statistical analysis
The distribution of lung function measures differed for
men and women. Therefore, sex specific quartiles of
FEV1, FVC, and FEV1-to-FVC ratio were created. Quar-
tiles were chosen instead of specific thresholds (e.g.,
FEV1-to-FVC ratio < 0.70) as few participants met the
threshold criteria. Additionally, an association between
lower lung function in the normal range and higher
blood pressure variability would provide stronger evi-
dence of a possible mechanistic relationship. Participant
characteristics were calculated by quartile of FEV1, FVC
and FEV1-to-FVC ratio, separately. We analyzed the
pairwise associations of three exposures (FEV1, FVC and
the FEV1-to-FVC ratio) with two outcomes (SDdn and
ARV) for SBP and DBP, separately. Below we describe
the analyses for the association between FEV1 and SDdn
of SBP. Identical analyses were conducted for FVC and
FEV1-to-FVC ratio and for the outcomes of ARV of SBP
and SDdn and ARV of DBP.
Mean SDdn of SBP was calculated by quartile of FEV1.
Next, the differences in SDdn of SBP for each of the
three highest quartiles of FEV1, compared to the lowest
quartile (the reference category), were calculated using
linear regression. Two models were estimated. The ini-
tial model included adjustment for age and sex. A subse-
quent model had additional adjustment for pack years of
cigarette smoking, physical activity, BMI, diabetes, total
and HDL-cholesterol, statin use, history of stroke and
myocardial infarction, eGFR, albuminuria, C-reactive
protein, mean daytime SBP and the classes of antihyper-
tensive medications being taken. Since lung function and
BPV have each been associated with sex, smoking status,
antihypertensive medication use and BP control, analyses
were performed to assess the association between FEV1,
FVC and FEV1-to-FVC ratio and SDdn in subgroups de-
fined by sex (male/female), smoking status (never,
former, current), antihypertensive medication use (yes/
no) and controlled clinic BP (yes/no). Two-sided p-
values < 0.05 were considered statistically significant. All
analyses were conducted using SAS version 9.3 (SAS In-
stitute, Research Triangle Park, NC).
Results
Participant characteristics
Participants in the lowest quartile of FEV1 had higher
mean height, weight and BMI, lower physical activity
levels and a higher proportion was current smokers
(Table 1) compared to the highest quartile. Also, the
prevalence of diabetes, a history of stroke and myocar-
dial infarction, hypertension, reduced eGFR, albuminuria
and statin use was higher in the lowest versus highest
quartile of FEV1. Mean daytime SBP was higher and an-
tihypertensive medication use was more common for
participants in the lowest versus highest quartile of
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Table 1 Baseline characteristics for Jackson Heart Study participants by quartiles of forced-expiratory-volume-in-1-second and
forced-vital-capacity
Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest)
Forced expiratory volume in 1 s
(n = 251) (n = 253) (n = 253) (n = 251)
FEV1 range in Men, percent predicted <80.7 80.7 to 91.8 91.8 to 101.1 ≥101.1
FEV1 range in Women, percent predicted <83.8 83.8 to 95.4 95.4 to 106.8 ≥106.8
Age, years 59.8 ± 10.4 57.7 ± 10.8 57.9 ± 11.0 61.0 ± 11.1
Male, % 31.9 32.0 32.0 31.9
Height, cm 170.3 ± 9.4 168.6 ± 9.4 167.7 ± 8.6 166.1 ± 8.7
Weight, kg 92.3 ± 19.1 90.2 ± 20.5 85.3 ± 19.3 84.3 ± 19.3
BMI, kg/m2 31.8 ± 6.1 31.8 ± 7.3 30.3 ± 6.2 30.5 ± 5.5
Obese, % 60.4 51.0 45.1 43.8
Physical activity scorea, exercise units 8.2 ± 2.6 8.2 ± 2.3 8.4 ± 2.6 8.5 ± 2.6
Cigarette pack years 9.4 ± 18.3 8.8 ± 17.1 4.5 ± 10.8 6.3 ± 13.8
Smoking status, %
Never 63.8 64.4 73.9 68.9
Former 21.5 17.4 19.4 24.3
Current 13.2 15.4 5.9 5.2
Diabetes, % 31.1 27.1 19.9 19.3
Total cholesterol, mg/dL 199.6 ± 37.1 201.1 ± 41.2 199.9 ± 37.4 203.6 ± 44.1
High-density lipoprotein, mg/dL 53.4 ± 15.8 54.0 ± 14.5 52.8 ± 14.9 55.2 ± 15.0
Statin use, % 14.7 14.7 13.6 13.1
History of stroke, % 5.2 4.4 1.2 4.4
History of myocardial infarction, % 10.0 7.1 5.9 6.4
eGFR < 60 ml/min/m2, % 12.6 6.4 7.2 8.8
ACR≥ 30, % 9.2 9.5 5.1 8.8
High sensitivity c-reactive protein, mg/L 3.5 (1.5 – 6.6) 3.0 (1.4 – 5.7) 2.8 (1.1 – 5.6) 2.2 (0.9 – 4.6)
Mean daytime systolic blood pressure, mm Hg 131.0 ± 14.8 129.7 ± 13.4 128.5 ± 12.7 128.4 ± 13.0
Mean daytime diastolic blood pressure, mm Hg 77.0 ± 9.4 78.2 ± 9.4 78.4 ± 9.2 77.6 ± 9.0
Hypertension, % 72.1 64.8 66.0 61.8
Antihypertensive medication useb, % 67.7 58.5 55.7 55.4
Antihypertensive medication classesb, %
Diuretic 72.6 65.7 62.4 70.5
Beta blocker 28.7 24.3 23.3 17.4
Calcium channel blocker 39.5 37.9 33.1 35.6
Angiotensin converting enzyme inhibitors 44.0 39.3 33.1 39.4
Angiotensin receptor blockers 15.3 8.6 14.3 10.6
Forced vital capacity
(n = 251) (n = 253) (n = 253) (n = 251)
FVC range in men, percent predicted <81.4 81.4 to 90.4 90.4 to 99.8 ≥99.8
FVC range in Women, percent predicted <83.3 83.3 to 94.2 94.2 to 105.2 ≥105.2
Age, years 59.5 ± 10.2 57.3 ± 10.5 58.4 ± 11.1 61.1 ± 11.5
Male, % 31.9 32.0 32.0 31.9
Height, cm 170.1 ± 9.8 168.2 ± 8.8 167.6 ± 8.5 166.8 ± 9.1
Weight, kg 93.9 ± 19.7 89.4 ± 20.9 85.6 ± 16.9 83.2 ± 17.6
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FEV1. Similar associations were present between par-
ticipant characteristics and quartiles of FVC (Table 1).
Additional file 1: Table S1 reports participant character-
istics by quartile of FEV1-to-FVC ratio.
FEV1 and FVC with day-night standard deviation and
average real variability of BP
There were no graded associations of lower quartiles of
FEV1 and, separately, FVC with higher mean SDdn of
SBP (Table 2). An association between FEV1 and SDdn
of SBP was present after adjustment for age and sex but
was attenuated after multivariable adjustment. The asso-
ciation between lower FVC with higher SDdn of SBP
after adjustment for age and sex was attenuated after full
multivariable adjustment. FEV1 and FVC were not asso-
ciated with SDdn of DBP before or after multivariable
adjustment. Associations were not present between
FEV1 and FVC with ARV of SBP and DBP (Table 3).
FEV1-to-FVC ratio with day-night standard deviation and
average real variability of BP
A graded association between lower quartiles of FEV1-
to-FVC ratio with higher mean SDdn and ARV of SBP
and DBP was not present (Table 4). FEV1-to-FVC ratio
was not associated with SDdn or ARV of SBP and DBP
before or after multivariable adjustment.
Sub-group analyses
Within each sub-group investigated, lower quartiles of
FEV1 were not associated with higher mean SDdn of SBP
and DBP (Additional file 2: Table S2). There were no as-
sociations between FVC and quartiles of SDdn of SBP
Table 1 Baseline characteristics for Jackson Heart Study participants by quartiles of forced-expiratory-volume-in-1-second and
forced-vital-capacity (Continued)
BMI, kg/m2 32.4 ± 6.2 31.6 ± 7.1 30.5 ± 5.9 29.9 ± 5.9
Obese, % 63.2 53.4 45.5 38.3
Physical activity scorea, exercise units 8.1 ± 2.5 8.3 ± 2.4 8.3 ± 2.6 8.6 ± 2.7
Cigarette pack years 7.9 ± 15.6 7.9 ± 16.4 6.0 ± 13.8 7.1 ± 15.5
Smoking status, %
Never 67.7 64.0 71.9 67.3
Former 17.5 20.6 19.8 24.7
Current 12.4 13.8 7.1 6.4
Diabetes, % 32.8 23.0 23.5 18.1
Total cholesterol, mg/dL 201.1 ± 40.9 200.6 ± 37.9 20.6 ± 42.0 199.0 ± 39.5
High-density lipoprotein, mg/dL 53.7 ± 15.3 53.1 ± 14.6 53.4 ± 15.3 55.2 ± 15.1
Statin use, % 17.3 10.0 15.2 13.6
History of stroke, % 5.2 4.4 2.4 3.2
History of myocardial infarction, % 10.0 5.9 5.1 8.4
eGFR < 60 ml/min/m2, % 11.4 7.5 4.8 11.3
ACR≥ 30, % 12.8 6.3 6.3 7.2
High sensitivity c-reactive protein, mg/L 3.4 (1.7 – 6.6) 3.1 (1.2 – 5.7) 2.8 (1.2 – 5.7) 1.9 (0.9 – 4.1)
Mean daytime systolic blood pressure, mm Hg 131.4 ± 14.5 129.2 ± 12.9 129.5 ± 13.1 128.6 ± 13.3
Mean daytime diastolic blood pressure, mm Hg 76.9 ± 9.3 78.8 ± 9.4 77.8 ± 8.7 77.6 ± 9.4
Prevalent hypertension, % 72.5 66.0 65.2 61.0
Antihypertensive medication useb, % 67.7 58.1 56.5 55.0
Antihypertensive medicationsb, %
Diuretic 74.1 61.2 64.5 71.7
Beta blocker 23.4 28.8 23.9 18.1
Calcium channel blocker 41.1 35.3 37.0 32.3
Angiotensin converting enzyme inhibitors 45.6 33.8 37.0 39.4
Angiotensin receptor blockers 12.7 11.5 15.2 9.5
Numbers in table are percentages or mean ± standard deviation except high-sensitivity c-reactive protein which is median (25th – 75th percentiles)
aHigher score =more physical activity
eGFR: estimated glomerular filtration rate; ACR: albumin to creatinine ratio
bAmong participants taking ≥ 1 antihypertensive medication
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and DBP in each sub-group except for lower quartiles of
FVC with higher SDdn of SBP and DBP in participants not
taking antihypertensive medications and SDdn of DBP in
those without controlled blood pressure (Additional file 3:
Tables S3). After multivariable adjustment, there were no
associations across quartiles of FEV1 or FVC with SDdn of
SBP and DBP in any of the sub-groups. There were no as-
sociations across quartiles of FEV1-to-FVC ratio with
SDdn of SBP and DBP (Additional file 4: Table S4).
Discussion
The current analysis of a large, community-based sample
of AAs tested the hypothesis that reduced lung function
is associated with higher 24-hour BPV. Higher quartiles
of FEV1, FVC and FEV1-to-FVC ratio were not associ-
ated with higher SDdn and ARV of SBP and DBP in un-
adjusted analyses and after multivariable adjustment.
Additionally, no associations were present between lung
function and BPV in sub-groups defined by sex, smoking
status, antihypertensive medication use and BP control.
Older age, male sex, AA race, higher 24-hour mean SBP,
inflammation, emotion, physical activity, environmental
temperature, food, and alcohol and tobacco consumption
have been associated with higher BPV [16, 17]. Reduced
lung function has been associated with several of these fac-
tors [13–15]. These shared associations provided a founda-
tion for the hypothesis of the current study that reduced
lung function would be associated with higher BPV. Al-
though there was an association between reduced FEV1 and
FVC and higher SDdn of SBP after adjustment for age and
sex, it was no longer present after multivariable adjustment.
One way the sympathetic nervous system controls car-
diac output, and may subsequently influence BPV, is
through lung function. Impaired lung function increases
the cardiac oxygen supply-to-demand ratio resulting in
higher cardiac output and possibly higher BPV [9]. Two
prior studies using beat-to-beat BP measurements have
suggested an association between reduced lung function
and increased BPV [10, 11]. In both studies, systolic
BPV was measured using a continuous 5-minute BP
Table 2 Differences in day-night standard deviation of blood pressure across quartiles of forced-expiratory-volume-in-1-second and
forced-vital-capacity
Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest) p-trend
Forced expiratory volume in 1 s
Systolic blood pressure (n = 251) (n = 253) (n = 253) (n = 251)
Mean ± standard deviation 9.5 ± 2.5 9.4 ± 2.4 9.1 ± 2.3 9.3 ± 2.6 0.111
Model 1, β (95 % CI) 0 (ref) 0.0 (−0.4 to 0.4) −0.4 (−0.8 to 0.1) −0.3 (−0.7 to 0.1) 0.041
Model 2, β (95 % CI) 0 (ref) 0.1 (−0.4 to 0.5) −0.1 (−0.5 to 0.3) −0.0 (−0.4 to 0.4) 0.775
Diastolic blood pressure
Mean ± standard deviation 8.1 ± 2.1 8.2 ± 2.1 8.1 ± 2.3 8.0 ± 2.0 0.318
Model 1, β (95 % CI) 0 (ref) 0.0 (−0.4 to 0.4) −0.1 (−0.4 to 0.3) −0.2 (−0.6 to 0.2) 0.321
Model 2, β (95 % CI) 0 (ref) −0.1 (−0.5 to 0.3) −0.1 (−0.5 to 0.3) −0.2 (−0.6 to 0.2) 0.393
Forced vital capacity
Systolic blood pressure (n = 251) (n = 253) (n = 253) (n = 251)
Mean ± standard deviation 9.6 ± 2.5 9.3 ± 2.5 9.1 ± 2.4 9.3 ± 2.4 0.054
Model 1, β (95 % CI) 0 (ref) −0.2 (−0.6 to 0.2) −0.5 (−0.9 to −0.1) −0.5 (−0.9 to −0.1) 0.009
Model 2, β (95 % CI) 0 (ref) −0.1 (−0.6 to 0.3) −0.3 (−0.7 to 0.2) −0.1 (−0.5 to 0.3) 0.495
Diastolic blood pressure
Mean ± standard deviation 8.3 ± 2.1 8.1 ± 2.3 7.8 ± 2.1 8.1 ± 2.1 0.155
Model 1, β (95 % CI) 0 (ref) −0.1 (−0.5 to 0.2) −0.5 (−0.8 to −0.1) −0.2 (−0.6 to 0.2) 0.157
Model 2, β (95 % CI) 0 (ref) −0.3 (−0.7 to 0.1) −0.5 (−0.9 to −0.1) −0.1 (−0.5 to 0.3) 0.348
Forced expiratory volume in 1 s quartile cut points (lowest to highest quartile):
Men: < 80.7, 80.7 to 91.8, 91.8 to 101.1, and ≥ 101.1
Women: < 83.8, 83.8 to 95.4, 95.4 to 106.8, and ≥ 106.8
Forced vital capacity quartile cut points (lowest to highest quartile):
Men: < 81.4, 81.4 to 90.4, 90.4 to 99.8, and ≥ 99.8
Women: < 83.3, 83.3 to 94.2, 94.2 to 105.2, and ≥ 105.2
CI: confidence interval
Model 1: adjustment for demographics (age and sex)
Model 2: Adjustment for Model 1 variables plus behaviors (pack years of cigarette smoking, physical activity, and body mass index), co-morbid conditions (diabetes, total
and HDL-cholesterol and statin use, history of stroke and history of myocardial infarction), kidney function (estimated glomerular filtration rate and albuminuria), markers
of inflammation (C-reactive protein), mean daytime SBP or DBP and antihypertensive medication classes being taken
Booth III et al. BMC Cardiovascular Disorders  (2016) 16:6 Page 6 of 10
recording. Each of these studies found an association be-
tween lower FEV1 and FVC and higher beat-to-beat sys-
tolic BPV. However, many factors during a short
measurement period that promote an elevated breathing
rate response, including increased stress/anxiety, may in-
fluence beat-to-beat BPV. The current study estimated
BPV over a longer period of time using ABPM and no
association was present between reduced lung function
and BPV. The results herein suggest that investigations
should be undertaken to determine the role of other
possible mechanisms, such as neuro-hormonal activa-
tion, of higher BPV [27]. For example, hypoxia can in-
crease plasma norepinephrine, norepinephrine myocardial
turnover and cardiac oxygen demand [27]. The effect
of the sympathetic nervous system activity becoming
elevated and poor cardiac function may result in re-
duced lung function [27]. Compared with breathing
mechanics, gas exchange/diffusion, measurable by
plethysmography, and other neuro-hormonal activators
may be important factors contributing to higher BPV
and CVD risk.
BPV derived from ABPM has been associated with
an increased risk for CVD and all-cause mortality
[12, 26, 28]. For example, in a pooled cohort of 8938
individuals, the hazard ratio (95 % confidence inter-
val) of mortality associated with each standard devi-
ation higher SDdn SBP and DBP was 1.08 (1.01 –
1.16) and 1.16 (1.09 – 1.23), respectively [12]. Similar
associations were present for ARV [12]. Despite the
results of the current study, BPV still remains an im-
portant risk factor for CVD. However, the null asso-
ciation between reduced lung function and higher
BPV of the current study suggests that BPV does not
mediate the association of lung function with CVD
outcomes reported in prior studies [1, 5–8, 29–34].
Future studies should consider investigating whether
reducing BPV will lower the risk for target-organ
damage and CVD-related outcomes.
Table 3 Differences in average real variability of blood pressure across quartiles of forced-expiratory-volume-in-1-second and forced-
vital-capacity
Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest) p-trend
Forced expiratory volume in 1 s
Systolic blood pressure (n = 251) (n = 253) (n = 253) (n = 251)
Mean ± standard deviation 8.8 ± 2.0 8.6 ± 2.0 8.7 ± 2.1 8.7 ± 2.2 0.593
Model 1, β (95 % CI) 0 (ref) −0.1 (−0.4 to 0.3) 0.0 (−0.3 to 0.4) −0.2 (−0.6 to 0.1) 0.349
Model 2, β (95 % CI) 0 (ref) 0.0 (−0.3 to 0.4) 0.2 (−0.2 to 0.5) 0.0 (−0.3 to 0.4) 0.627
Diastolic blood pressure
Mean ± standard deviation 7.7 ± 2.0 7.6 ± 2.0 7.7 ± 2.3 7.6 ± 2.1 0.635
Model 1, β (95 % CI) 0 (ref) −0.1 (−0.5 to 0.2) −0.0 (−0.4 to 0.3) −0.1 (−0.5 to 0.2) 0.646
Model 2, β (95 % CI) 0 (ref) −0.2 (−0.6 to 0.2) −0.0 (−0.4 to 0.4) −0.1 (−0.4 to 0.3) 0.993
Forced vital capacity
Systolic blood pressure (n = 251) (n = 253) (n = 253) (n = 251)
Mean ± standard deviation 8.9 ± 1.9 8.6 ± 2.2 8.6 ± 2.0 8.8 ± 2.1 0.617
Model 1, β (95 % CI) 0 (ref) −0.1 (−0.5 to 0.2) −0.3 (−0.6 to 0.1) −0.2 (−0.5 to 0.2) 0.263
Model 2, β (95 % CI) 0 (ref) −0.1 (−0.4 to 0.3) −0.1 (−0.5 to 0.2) 0.1 (−0.3 to 0.4) 0.856
Diastolic blood pressure
Mean ± standard deviation 7.9 ± 2.0 7.6 ± 2.2 7.5 ± 2.1 7.7 ± 2.2 0.212
Model 1, β (95 % CI) 0 (ref) −0.3 (−0.6 to 0.1) −0.4 (−0.8 to −0.0) −0.2 (−0.6 to 0.2) 0.221
Model 2, β (95 % CI) 0 (ref) −0.3 (−0.7 to 0.0) −0.4 (−0.8 to −0.0) −0.1 (−0.4 to 0.3) 0.742
Forced expiratory volume in 1 s quartile cut points (lowest to highest quartile):
Men: < 80.7, 80.7 to 91.8, 91.8 to 101.1, and ≥ 101.1
Women: < 83.8, 83.8 to 95.4, 95.4 to 106.8, and ≥ 106.8
Forced vital capacity quartile cut points (lowest to highest quartile):
Men: < 81.4, 81.4 to 90.4, 90.4 to 99.8, and ≥ 99.8
Women: < 83.3, 83.3 to 94.2, 94.2 to 105.2, and ≥ 105.2
CI: confidence interval
Model 1: adjustment for demographics (age and sex)
Model 2: Adjustment for Model 1 variables plus behaviors (pack years of cigarette smoking, physical activity, and body mass index), co-morbid conditions (diabetes, total
and HDL-cholesterol and statin use, history of stroke and history of myocardial infarction), kidney function (estimated glomerular filtration rate and albuminuria), markers
of inflammation (C-reactive protein), mean daytime SBP or DBP and antihypertensive medication classes being taken
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Epidemiologic studies have reported an association be-
tween reduced lung function and an increased risk of
CVD [35]. For example, among 7 058 men and 8353
women in the Renfrew and Paisley study, the hazard ra-
tio (95 % confidence interval) for ischemic heart disease
associated with the lowest versus highest quintile of
FEV1 expressed as percentage of predictive value (<73
versus >107 for men and <75 and >112 for women) was
1.56 (1.26 – 1.92) and 1.88 (1.44 – 2.47), respectively [7].
Additionally, CVD is the primary cause of death among
individuals with reduced lung function [35]. Although
an association between lower lung function and incident
CVD has been reported in several studies, the under-
lying mechanism by which reduced lung function pre-
dicts CVD outcomes remains unclear. The current
results suggest that reduced lung function is not asso-
ciated with higher 24-hour BPV suggesting other
mechanisms underlie the increased CVD risk among
individuals with reduced lung function. Future studies
should investigate factors that explain the association
between reduced lung function and increased CVD risk.
Several limitations should be considered when inter-
preting the results from the current analysis. Lung func-
tion and ABPM have only been measured at a single
JHS visit. The cross-sectional study design prevented the
assessment of the longitudinal association between lung
function and BPV. Additionally, not all JHS participants
had ABPM measurements. However, we do not believe
our results are due to lack of power because the magni-
tude of the association between lung function and BPV
was too small to be clinically meaningful. Despite these
limitations, there are several strengths. The JHS is a
large population-based investigation of AAs. Compared
to whites, AAs have lower lung function, higher BPV
and an increased risk for hypertension and CVD. Few
studies that have measured ABP included AAs. Finally,
measurements of lung function, BPV and covariates
were conducted following a standardized protocol.
Table 4 Differences in blood pressure for measures of blood pressure variability across quartiles of forced-expiratory-volume-in-1-
second-to-forced-vital-capacity ratio
Forced expiratory volume in 1 s to forced vital capacity ratio
Quartile 1 (lowest) Quartile 2 Quartile 3 Quartile 4 (highest) p-trend
Day-night standard deviation
Systolic blood pressure (n = 251) (n = 253) (n = 253) (n = 251)
Mean ± standard deviation 9.3 ± 2.6 9.2 ± 2.2 9.4 ± 2.5 9.3 ± 2.5 0.680
Model 1, β (95 % CI) 0 (ref) −0.1 (−0.5 to 0.3) 0.2 (−0.2 to 0.6) −0.1 (−0.5 to 0.4) 0.890
Model 2, β (95 % CI) 0 (ref) −0.0 (−0.5 to 0.4) 0.1 (−0.4 to 0.5) −0.1 (−0.5 to 0.4) 0.314
Diastolic blood pressure
Mean ± standard deviation 8.1 ± 2.2 8.1 ± 2.0 8.2 ± 2.3 8.0 ± 2.1 0.685
Model 1, β (95 % CI) 0 (ref) 0.0 (−0.4 to 0.4) 0.1 (−0.3 to 0.4) −0.1 (−0.5 to 0.3) 0.688
Model 2, β (95 % CI) 0 (ref) −0.0 (−0.4 to 0.3) −0.2 (−0.6 to 0.2) −0.2 (−0.6 to 0.2) 0.180
Average real variability
Systolic blood pressure
Mean ± standard deviation 8.7 ± 2.2 8.6 ± 2.0 8.8 ± 2.0 8.8 ± 2.1 0.570
Model 1, β (95 % CI) 0 (ref) −0.1 (−0.5 to 0.2) 0.1 (−0.2 to 0.5) −0.0 (−0.4 to 0.3) 0.765
Model 2, β (95 % CI) 0 (ref) −0.1 (−0.5 to 0.2) 0.1 (−0.3 to 0.4) 0.0 (−0.3 to 0.4) 0.702
Diastolic blood pressure
Mean ± standard deviation 7.6 ± 2.1 7.7 ± 2.0 7.7 ± 2.2 7.6 ± 2.1 0.888
Model 1, β (95 % CI) 0 (ref) 0.0 (−0.3 to 0.4) 0.1 (−0.2 to 0.5) 0.0 (−0.4 to 0.4) 0.878
Model 2, β (95 % CI) 0 (ref) −0.1 (−0.4 to 0.3) −0.1 (−0.5 to 0.3) −0.2 (−0.6 to 0.2) 0.297
Forced expiratory volume in 1 s: Forced vital capacity ratio quartile cut points (lowest to highest quartile):
Men: < 0.96, 0.96 to 1.02, 1.02 to 1.07, and ≥ 1.07
Women: < 0.97, 0.97 to 1.03, 1.03 to 1.07, and ≥ 1.07
CI: confidence interval
Model 1: adjustment for demographics (age and sex)
Model 2: Adjustment for Model 1 variables plus behaviors (cigarette smoking, physical activity, and body mass index), co-morbid conditions (diabetes, total and
HDL-cholesterol and statin use, history of stroke and history of myocardial infarction), kidney function (estimated glomerular filtration rate and albuminuria),
markers of inflammation (C-reactive protein), mean daytime SBP or DBP and antihypertensive medication classes being taken
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Conclusion
In conclusion, although individuals in the current study
with lower lung function had higher 24-hour BPV, no
association was present after multivariable adjustment.
Future studies are needed to identify the factors under-
lying higher levels of BPV. Studies are also needed to de-
termine factors that mediate the increased CVD risk
associated with reduced lung function.
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